In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on SELLAS Life Sciences Group (SLS – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.55.
According to TipRanks, McCarthy is an analyst with an average return of -30.3% and a 22.44% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, SELLAS Life Sciences Group, and Achieve Life Sciences.
SELLAS Life Sciences Group has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See today’s best-performing stocks on TipRanks >>
Based on SELLAS Life Sciences Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.84 million. In comparison, last year the company had a GAAP net loss of $8.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
Read More on SLS:
- SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
- Sellas Life Sciences reports Q2 EPS (31c), consensus (35c)
- SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
- Sellas Life Sciences reports data from Phase 1 study of galinpepimut-S
- SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
